Important advances in the field of anti-dengue virus research
Important advances in the field of anti-dengue virus research
复制标题
DOI：
10.3851/imp1690
复制
发表时间：
2011-01-01
影响因子：
--
通讯作者：
Shresta, Sujan
中科院分区：
文献类型：
--
作者：
Julander, Justin G.;Perry, Stuart T.;Shresta, Sujan
目前还没有获得许可的抗病毒药物可用于治疗登革热病毒（DENV），这种病毒在世界各地的热带地区造成显着的发病率和死亡率，目前正在侵入美国南部。现有动物模型和细胞培养系统的最新改进对于阐明人类 DENV 发病机制非常重要，包括鉴定可能成为治疗 DENV 感染的潜在病毒和宿主蛋白。 AG129 小鼠模型是临床使用的抗病毒和候选疫苗开发的重大进展。它允许在相关系统中测试潜在的治疗方法，该系统表现出与人类观察到的疾病的某些方面相似的疾病。本综述重点关注 AG129 小鼠模型的最新进展，并讨论了过去一年中在现有细胞和动物模型系统中发现的活性化合物。
There are currently no licensed antivirals available for the treatment of dengue virus (DENV), which causes significant morbidity and mortality throughout tropical areas of the world and is now encroaching on the southern United States. Recent improvements in existing animal models and cell culture systems have been very important in elucidating the mechanisms of DENV pathogenesis in humans, including the identification of potential viral and host proteins that might be targeted for the treatment of DENV infection. The AG129 mouse model is a major advance in the development of antiviral and vaccine candidates for clinical use. It allows for testing of potential therapeutics in a relevant system that exhibits some aspects of disease that are similar to those observed in humans. This review focuses on recent developments in the AG129 mouse model and discusses compounds that have been found to be active in available cell and animal model systems within the past year.